High density lipoproteins and atherosclerosis: Emerging aspects

Journal of Geriatric Cardiology

Volumn 9, Issue 4, 2012, Pages 401-407

  Sala, Federica ^a   Catapano, Alberico Luigi ^a   Norata, Giuseppe Danilo ^a  

^a NONE

Author keywords

Apolipoprotein; High density lipoproteins; Immune response; Sphingosine 1 phosphate

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN C; APOLIPOPROTEIN D; APOLIPOPROTEIN E; ARYLDIALKYLPHOSPHATASE 1; CLUSTERIN; FINGOLIMOD; GROWTH FACTOR RECEPTOR; HIGH DENSITY LIPOPROTEIN; LIPOPOLYSACCHARIDE BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PENTRAXIN 3; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; PROTEIN KINASE C; PROTEIN TYROSINE KINASE; SCAVENGER RECEPTOR BI; SPHINGOSINE 1 PHOSPHATE; T LYMPHOCYTE RECEPTOR;

ACUTE PHASE RESPONSE; ADAPTIVE IMMUNITY; ANTIGEN PRESENTING CELL; ANTIOXIDANT ACTIVITY; ATHEROGENESIS; ATHEROSCLEROSIS; CELL DIFFERENTIATION; CHOLESTEROL TRANSPORT; ENDOTOXEMIA; HUMAN; HYDROPHOBICITY; IMMUNOCOMPETENT CELL; LIPID RAFT; NONHUMAN; PROTEIN EXPRESSION; PROTEIN SECRETION; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION;

EID: 84874079949     PISSN: 16715411     EISSN: None     Source Type: Journal    
DOI: 10.3724/SP.J.1263.2011.12282     Document Type: Review

References (76)

1. Glass CK, Witztum JL Atherosclerosis. the road ahead. Cell. 2001; 104: 503-516.
2. Hansson GK, Hermansson A. The immune system in atherosclerosis. Nat Immunol. 2011; 12: 204-212.
3. Navab M, Ananthramaiah GM, Reddy S.T., et al The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. J Lipid Res. 2004; 45: 993-1007.
4. von Eckardstein A., Nofer JR, Assmann G. High density lipoproteins and arteriosclerosis. Arterioscler Thromb Vasc Biol. 2001; 21: 13-27. Role of cholesterol efflux and reverse cholesterol transport.
5. Khera AV, Cuchel M, de la Llera-Moya M, et al Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med. 2011; 364: 127-135.
6. Duong M, Collins HL, Jin W, et al Relative contributions of ABCA1 and SR-BI to cholesterol efflux to serum from fibroblasts and macrophages. Arterioscler Thromb Vasc Biol. 2006; 26: 541-547.
7. Norata GD, Pirillo A, Ammirati E., et al Emerging role of high density lipoproteins as a player in the immune system. Atherosclerosis. 2012; 220: 11-21.
8. Simons K, Toomre D. Lipid rafts and signal transduction. Nat Rev Mol Cell Biol. 2000; 1: 31-39.
9. Calabresi L, Gomaraschi M, Franceschini G. Endothelial protection by high-density lipoproteins: from bench to bedside. Arterioscler Thromb Vasc Biol. 2003; 23: 1724-1731.
10. Collet X, Marcel YL, Tremblay N, et al Evolution of mammalian apolipoprotein A-I and conservation of antigenicity: correlation with primary and secondary structure. J Lipid Res. 1997; 38: 634-644.
11. Hansson GK, Bjorkholm M. Medicine. Tackling two diseases with HDL. Science. 2010; 328: 1641-1642.
12. Yvan-Charvet L., Pagler T, Gautier E.L., et al ATP-binding cassette transporters and HDL suppress hematopoietic stem cell proliferation. Science. 2010; 328: 1689-1693.
13. Norata GD, Pirillo A, Catapano AL HDLs, immunity, and atherosclerosis. Curr Opin Lipidol. 2011; 22: 410-416.
14. Norata GD, Marchesi P, Pirillo A., et al Long pentraxin 3, a key component of innate immunity, is modulated by high-density lipoproteins in endothelial cells. Arterioscler Thromb Vasc Biol. 2008; 28: 925-931.
15. Deban L, Russo RC, Sironi M, et al Regulation of leukocyte recruitment by the long pentraxin PTX3. Nat Immunol. 2010; 11: 328-334.
16. Norata GD, Garlanda C, Catapano AL The long pentraxin PTX3: a modulator of the immunoinflammatory response in atherosclerosis and cardiovascular diseases. Trends Cardiovasc Med. 2010; 20: 35-40.
17. Norata GD, Marchesi P, Pulakazhi Venu VK, et al Deficiency of the long pentraxin PTX3 promotes vascular inflammation and atherosclerosis. Circulation. 2009; 120: 699-708.
18. Khovidhunkit W, Kim MS, Memon R.A., et al Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res. 2004; 45: 1169-1196.
19. Coetzee GA, Strachan AF, van der Westhuyzen DR, et al Serum amyloid Acontaining human high density lipoprotein 3. Density, size, and apolipoprotein composition. J Biol Chem. 1986; 261: 9644-9651.
20. Han J, Ulevitch RJ Limiting inflammatory responses during activation of innate immunity. Nat Immunol. 2005; 6: 1198-1205.
21. Rittirsch D, Flierl MA, Ward PA Harmful molecular mechanisms in sepsis. Nat Rev Immunol. 2008; 8: 776-787.
22. Wurfel MM, Kunitake ST, Lichenstein H, et al Lipopolysaccharide (LPS)-binding protein is carried on lipoproteins and acts as a cofactor in the neutralization of LPS. J Exp Med. 1994; 180: 1025-1035.
23. Levine DM, Parker TS, Donnelly T.M., et al In vivo protection against endotoxin by plasma high density lipoprotein. Proc Natl Acad Sci U S A. 1993; 90: 12040-12044.
24. Hubsch AP, Powell FS, Lerch P.G., et al A reconstituted, apolipoprotein A-I containing lipoprotein reduces tumor necrosis factor release and attenuates shock in endotoxemic rabbits. Circ Shock. 1993; 40: 14-23.
25. Birjmohun RS, van Leuven SI, Levels JH, et al High-density lipoprotein attenuates inflammation and coagulation response on endotoxin challenge in humans. Arterioscler Thromb Vasc Biol. 2007; 27: 1153-1158.
26. Cai L, Ji A, de Beer FC, et al SR-BI protects against endotoxemia in mice through its roles in glucocorticoid production and hepatic clearance. J Clin Invest. 2008; 118: 364-375.
27. Gupta H, Dai L, Datta G., et al Inhibition of lipopolysaccharide-induced inflammatory responses by an apolipoprotein AI mimetic peptide. Circ Res. 2005; 97: 236-243.
28. Tobias PS, McAdam KP, Soldau K, et al Control of lipopolysaccharide-high- density lipoprotein interactions by an acute-phase reactant in human serum. Infect Immun. 1985; 50: 73-76.
29. Munford RS, Andersen JM, Dietschy JM Sites of tissue binding and uptake in vivo of bacterial lipopolysaccharide-high density lipoprotein complexes: studies in the rat and squirrel monkey. J Clin Invest. 1981; 68: 1503-1513.
30. Cabana VG, Siegel JN, Sabesin SM Effects of the acute phase response on the concentration and density distribution of plasma lipids and apolipoproteins. J Lipid Res. 1989; 30: 39-49.
31. Menschikowski M, Hagelgans A, Siegert G. Secretory phospholipase A2 of group IIA: is it an offensive or a defensive player during atherosclerosis and other inflammatory diseases? Prostaglandins Other Lipid Mediat. 2006; 79: 1-33.
32. Van Lenten B.J., Navab M, Shih D., et al The role of high-density lipoproteins in oxidation and inflammation. Trends Cardiovasc Med. 2001; 11: 155-161.
33. Feingold KR, Memon RA, Moser A.H., et al Paraoxonase activity in the serum and hepatic mRNA levels decrease during the acute phase response. Atherosclerosis. 1998; 139: 307-315.
34. Cao Y, Stafforini DM, Zimmerman G.A., et al Expression of plasma platelet-activating factor acetylhydrolase is transcriptionally regulated by mediators of inflammation. J Biol Chem. 1998; 273: 4012-4020.
35. Memon RA, Fuller J, Moser A.H., et al In vivo regulation of plasma platelet-activating factor acetylhydrolase during the acute phase response. Am J Physiol. 1999; 277: R94-R103.
36. Navab M, Anantharamaiah GM, Reddy S.T., et al HDL as a biomarker, potential therapeutic target, and therapy. Diabetes. 2009; 58: 2711-2717.
37. Banka CL, Yuan T, de Beer MC, et al Serum amyloid A (SAA): influence on HDL-mediated cellular cholesterol efflux. J Lipid Res. 1995; 36: 1058-1065.
38. McGillicuddy FC, de la Llera Moya M, Hinkle CC, et al. Inflammation impairs reverse cholesterol transport in vivo. Circulation. 2009; 119: 1135-1145.
39. Clifton PM, Mackinnon AM, Barter PJ Effects of serum amyloid A protein (SAA) on composition, size, and density of high density lipoproteins in subjects with myocardial infarction. J Lipid Res. 1985; 26: 1389-1398.
40. Van Lenten B.J., Hama SY, de Beer FC, et al Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest. 1995; 96: 2758-2767.
41. Lusis AJ. Atherosclerosis. Nature. 2000; 407: 233-241.
42. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med. 1999; 340: 115-126.
43. Oram JF. ATP-binding cassette transporter A1 and cholesterol trafficking. Curr Opin Lipidol. 2002; 13: 373-381.
44. Wang X, Collins HL, Ranalletta M, et al Macrophage ABCA1 and ABCG1, but not SR-BI, promote macrophage reverse cholesterol transport in vivo. J Clin Invest. 2007; 117: 2216-2224.
45. Moudry R, Spycher MO, Doran JE Reconstituted high density lipoprotein modulates adherence of polymorphonuclear leukocytes to human endothelial cells. Shock. 1997; 7: 175-181.
46. Bensinger SJ, Bradley MN, Joseph S.B., et al LXR signaling couples sterol metabolism to proliferation in the acquired immune response. Cell. 2008; 134: 97-111.
47. Wilhelm AJ, Zabalawi M, Grayson J.M., et al Apolipoprotein A-I and its role in lymphocyte cholesterol homeostasis and autoimmunity. Arterioscler Thromb Vasc Biol. 2009; 29: 843-849.
48. Landry YD, Denis M, Nandi S., et al ATP-binding cassette transporter A1 expression disrupts raft membrane microdomains through its ATPase-related functions. J Biol Chem. 2006; 281: 36091-36101.
49. Kabouridis PS, Janzen J, Magee A.L., et al Cholesterol depletion disrupts lipid rafts and modulates the activity of multiple signaling pathways in T lymphocytes. Eur J Immunol. 2000; 30: 954-963.
50. Anderson HA, Hiltbold EM, Roche PA Concentration of MHC class II molecules in lipid rafts facilitates antigen presentation. Nat Immunol. 2000; 1: 156-162.
51. Jury EC, Flores-Borja F, Kabouridis PS Lipid rafts in T cell signalling and disease. Semin Cell Dev Biol. 2007; 18: 608-615.
52. Kabouridis PS. Lipid rafts in T cell receptor signalling. Mol Membr Biol. 2006; 23: 49-57.
53. Zeyda M, Stulnig TM Lipid Rafts & Co.: an integrated model of membrane organization in T cell activation. Prog Lipid Res. 2006; 45: 187-202.
54. Hiltbold EM, Poloso NJ, Roche PA MHC class II-peptide complexes and APC lipid rafts accumulate at the immunological synapse. J Immunol. 2003; 170: 1329-1338.
55. Poloso NJ, Roche PA Association of MHC class II-peptide complexes with plasma membrane lipid microdomains. Curr Opin Immunol. 2004; 16: 103-107.
56. Setterblad N, Roucard C, Bocaccio C., et al Composition of MHC class II-enriched lipid microdomains is modified during maturation of primary dendritic cells. J Leukoc Biol. 2003; 74: 40-48.
57. Eren E, Yates J, Cwynarski K., et al Location of major histocompatibility complex class II molecules in rafts on dendritic cells enhances the efficiency of T-cell activation and proliferation. Scand J Immunol. 2006; 63: 7-16.
58. Zilber MT, Setterblad N, Vasselon T., et al MHC class II/CD38/CD9: a lipid-raft-dependent signaling complex in human monocytes. Blood. 2005; 106: 3074-3081.
59. Murphy AJ, Woollard KJ, Hoang A, et al High-density lipoprotein reduces the human monocyte inflammatory response. Arterioscler Thromb Vasc Biol. 2008; 28: 2071-2077.
60. Hansson GK. Immune mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol. 2001; 21: 1876-1890.
61. Bobryshev YV, Lord RS Mapping of vascular dendritic cells in atherosclerotic arteries suggests their involvement in local immune-inflammatory reactions. Cardiovasc Res. 1998; 37: 799-810.
62. Niessner A, Weyand CM Dendritic cells in atherosclerotic disease. Clin Immunol. 134: 25-32.
63. Dopheide JF, Sester U, Schlitt A., et al Monocyte-derived dendritic cells of patients with coronary artery disease show an increased expression of costimulatory molecules CD40, CD80 and CD86 in vitro. Coron Artery Dis. 2007; 18: 523-531.
64. Kim KD, Lim HY, Lee H.G., et al Apolipoprotein A-I induces IL-10 and PGE2 production in human monocytes and inhibits dendritic cell differentiation and maturation. Biochem Biophys Res Commun. 2005; 338: 1126-1136.
65. Dykstra M, Cherukuri A, Sohn H.W., et al Location is everything: lipid rafts and immune cell signaling. Annu Rev Immunol. 2003; 21: 457-481.
66. Gupta N, DeFranco AL Lipid rafts and B cell signaling. Semin Cell Dev Biol. 2007; 18: 616-626.
67. Kabouridis PS, Jury EC Lipid rafts and T-lymphocyte function: implications for autoimmunity. FEBS Lett. 2008; 582: 3711-3718.
68. Pappu R, Schwab SR, Cornelissen I, et al Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate. Science. 2007; 316: 295-298.
69. Mandala S, Hajdu R, Bergstrom J., et al Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science. 2002; 296: 346-349.
70. Liu G, Yang K, Burns S., et al The S1P(1)-mTOR axis directs the reciprocal differentiation of T(H) 1 and T(reg) cells. Nat Immunol. 2010; 11: 1047-1056.
71. Scanu AM, Edelstein C. HDL: bridging past and present with a look at the future. Faseb J. 2008; 22: 4044-4054.
72. Nofer JR, Bot M, Brodde M., et al FTY720, a synthetic sphingosine 1 phosphate analogue, inhibits development of atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation. 2007; 115: 501-508.
73. Keul P, Tolle M, Lucke S., et al The sphingosine-1-phosphate analogue FTY720 reduces atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2007; 27: 607-613.
74. Blom T, Back N, Mutka A.L., et al FTY720 stimulates 27-hydroxycholesterol production and confers atheroprotective effects in human primary macrophages. Circ Res. 2010; 106: 720-729.
75. Ammirati E, Cianflone D, Banfi M., et al Circulating CD4+ CD25hiCD127lo regulatory T-Cell levels do not reflect the extent or severity of carotid and coronary atherosclerosis. Arterioscler Thromb Vasc Biol. 2010; 30: 1832-1841.
76. -/- mice. J Biol Chem. 2010; 285: 36158-36169.